Vimarsana
Biggest News Aggregation in the World

Page 14 - Inducement Plan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inducement Plan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inducement Plan Today - Breaking & Trending Today

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics, Inc. , a leading microbiome therapeutics company, today announced that on September 6, 2023, the Compensation and Talent Committee of Seres’ board of directors granted...

Rhythm Pharmaceuticals Announces New Employment Inducement Grants - Vimarsana News

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - Vimarsana News

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

WALTHAM - ImmunoGen, Inc., , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the compensation committee of the Company's Board of...

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc., , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors ...

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Vimarsana News

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to...